<DOC>
	<DOCNO>NCT02634346</DOCNO>
	<brief_summary>This study evaluate efficacy ALKS 3831 adult subject acute exacerbation schizophrenia .</brief_summary>
	<brief_title>A Study ALKS 3831 Adults With Acute Exacerbation Schizophrenia ( ENLIGHTEN-1 Study )</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Has body mass index ( BMI ) 18.0 40.0 kg/m^2 Meets criteria diagnosis schizophrenia Resides stable living situation hospitalize Is willing able provide governmentissued identification Additional criterion may apply Has psychiatric hospitalization 30 day 90 day screen Subject initiate first antipsychotic treatment within past 12 month , &lt; 1 year elapse since initial onset activephase schizophrenia symptom Subject pose current suicide risk Subject history treatment resistance Subject history poor inadequate response treatment olanzapine Subject require electroconvulsive therapy ( ECT ) treatment 2month period prior screen Subject diagnosis moderate severe alcohol drug use disorder Subject positive urine drug screen opioids , amphetamine/methamphetamine , phencyclidine , cocaine screen Additional criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Alkermes</keyword>
	<keyword>ALKS 3831</keyword>
	<keyword>Samidorphan</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Acute Exacerbation Schizophrenia</keyword>
</DOC>